Skip to content

    Hikal

    HIKALGood
    Healthcare·14 May 2025
    Management Summary

    Hikal reported a strong Q4 FY25 performance driven by operational leverage and cost initiatives, with significant EBITDA growth and margin expansion. The Pharma business is poised for continued growth in FY26, while the Crop Protection segment is expected to remain flat before resuming growth in FY27 due to ongoing market headwinds. The company is investing in new capabilities, R&D, and expanding its CDMO pipeline.

    Highlights

    8
    • Q4 FY25 Revenue amounted to ₹552 crores.

    • Q4 FY25 EBITDA was ₹123 crores, reflecting a 71% sequential growth and 31% Y-o-Y growth.

    • Q4 FY25 EBITDA margins improved by 410 basis points to 22.4%.

    • Full Year FY25 Revenue stood at ₹1,860 crores, with EBITDA at ₹328 crores, a margin of 17.7% (up 270 basis points YoY).

    • Pharma business is projected to grow 12-15% in FY26 with a corresponding increase in EBIT margins.

    • Crop Protection business is expected to have muted/flattish growth in FY26, with growth resuming in FY27.

    • The Board recommended a final dividend of ₹0.80 per share, bringing the total FY25 dividend to ₹1.40 per share (70% of face value).

    • The company consistently allocates 4-5% of its revenue towards R&D and plans ₹200 crores in capex each year for FY26 and FY27.

    Concerns

    1
    • Competitive pricing, especially from China, in the Crop Protection sector.

    What Changed3

    vs Q1 FY26

    Tone shiftMixed → GoodGuidance items16 → 12 (-4)Risks discussed4 → 5 (+1)
    Key financials

    Metrics

    9

    Periods

    2

    Q4 FY25

    3
    • Revenue
      ₹552 Cr
    • EBITDA
      ₹123 Cr
      YoY+31%QoQ+71%
    • EBITDA Margin
      22.4%

    FY25

    6
    • Revenue
      ₹1,860 Cr
    • EBITDA
      ₹328 Cr
    • EBITDA Margin
      17.7%
    • PAT
      ₹91 Cr
    • ROE
      7.3%

    Segment breakdown

    • Pharmaceutical Business₹351 Cr63.6%
    • Crop Protection Business₹201 Cr36.4%
    Donut· Share of Q4 FY25 Revenue

    Guidance & targets

    12
    CategoryTargetPriority
    Revenue
    Pharma Business Revenue Growth
    12-15%
    Medium
    Revenue
    Crop Protection Business Revenue Growth
    Muted/Flattish
    High
    Revenue
    Crop Protection Business Revenue Growth Resumption
    Growth to resume
    High
    Revenue
    Pharma Business Long-term Revenue Growth
    12-15%
    High
    Revenue
    Food Ingredient Project Peak Revenue
    Peak revenue
    Medium
    Profitability
    Pharma Business EBIT Margins
    Increase
    Medium
    Profitability
    PAT
    ₹160 crores
    Medium
    R&D
    R&D Spend as % of Revenue
    4-5%
    High
    Capex
    Annual Capex
    ₹200 crores
    High
    Capacity
    High-Potency Chemistry Lab Operational
    Operational
    High
    Product Launch
    CDMO Phase III Project Commercialization
    Commercial scale
    High
    Product Launch
    CDMO Phase III Project Launch
    Launched
    High

    Risks & concerns

    5
    RiskSeverity

    Geopolitical uncertainty, supply chain recalibration, and persistent cost pressures.

    The company acknowledges a complex backdrop but is taking decisive steps to strengthen core businesses.Management acknowledged

    medium

    Competitive pricing, especially from China, in the Crop Protection sector.

    This is a significant headwind, but the sector is undergoing a strategic shift expected to stabilize by FY26-27.Management acknowledged

    high

    Potential impact of US tariffs on Indian companies.

    Management notes the complexity and uncertainty of tariffs but has not seen direct customer indications of price changes yet; outsourcing trends continue.Analyst acknowledged

    medium

    Seasonality leading to heavy Q4 performance and dependency.

    Management is working to streamline operations and reduce Q4 dependency as products launch and validate.Analyst acknowledged

    low

    US FDA observations received in February.

    The company has responded to all observations and is awaiting the FDA's response, stating there was no data integrity issue.Analyst acknowledged

    medium

    Q&A highlights

    3

    “Yes, I think there's no change. We spoke about 2 different segments. We expect healthy growth in the Pharma business, which is on track. In fact, it may even be more accelerated than what we spoke earlier. The Crop business is where we expect flattish numbers for next year and it to resume in FY '27.”

    This question clarified the segment-specific growth expectations, confirming Pharma's strong outlook and Crop Protection's temporary stagnation before recovery.

    asked by Dhaval Shah from Girik Capital

    3 min read7 chapters

    Detailed Narrative

    01

    Q4 & FY25 Financial Performance Highlights

    Hikal reported a robust Q4 FY25 with revenue of ₹552 crores and EBITDA of ₹123 crores, marking a 71% sequential growth and 31% Y-o-Y growth in EBITDA. EBITDA margins significantly improved by 410 basis points to 22.4%. For the full year FY25, revenue stood at ₹1,860 crores, with EBITDA at ₹328 crores, translating to a 17.7% margin, an increase of 270 basis points from the previous year. The company also reported a PAT of ₹91 crores for FY25, with ROE at 7.3% and ROCE at 9.9%.

    02

    Pharma Business: Strong Growth Trajectory

    The Pharmaceutical business demonstrated strong momentum, reporting Q4 FY25 revenue of ₹351 crores and EBIT of ₹55 crores. For the full year, Pharma revenue was ₹1,168 crores with EBIT of ₹137 crores, an impressive 47% Y-o-Y growth in EBIT, expanding margins by 327 basis points. Management expects the Pharma business to achieve 12-15% revenue growth in FY26, accompanied by a corresponding increase in EBIT margins, driven by an uptick in volumes, new molecules, and a healthy CDMO pipeline.

    03

    Crop Protection: Navigating Headwinds and Strategic Shift

    The Crop Protection business recorded Q4 FY25 revenue of ₹201 crores with an EBIT of ₹36 crores (18% margin). For the full year, revenue was ₹692 crores and EBIT ₹79 crores (11.4% margin). This segment continues to face headwinds, particularly competitive pricing from China. Management anticipates muted or flattish growth for Crop Protection in FY26, but expects growth to resume in FY27, supported by strategic initiatives like establishing a Specialty Chemicals portfolio and advancing CDMO projects.

    04

    Animal Health Division Progress

    The Animal Health Division is making steady progress, with validation of eight products completed successfully under a long-term agreement with an innovator customer. These products are slated for commercial launches across key global markets in the upcoming quarters. The company is also actively engaging with multiple new innovator customers, observing significant positive momentum and building a healthy pipeline in this high-growth segment.

    05

    Investments in R&D and New Capabilities

    Hikal is committed to innovation, consistently allocating 4-5% of its revenue towards R&D. The company plans a capex of approximately ₹200 crores each for FY26 and FY27 to enhance capabilities and capacity. A new high-potency chemistry laboratory is being set up, expected to be operational by Q3 FY26, which will enable participation in more RFPs for NCEs and clinical stage materials, particularly for anticancer drugs.

    06

    CDMO Pipeline and Commercialization Outlook

    The CDMO segment continues to be a key strategic driver with a healthy pipeline of development programs. Two key starting material projects for new chemical entities are progressing well in Phase III trials and are expected to transition to commercial scale in 2026-27. One of these molecules may generate revenues in FY26, with a full launch ramp-up in 2027. The company is also working on 12-15 additional new opportunities, and its food ingredient project is on track to reach peak revenue within the next 2-3 years.

    07

    Regulatory and Market Dynamics

    The company acknowledged the complex global backdrop, including geopolitical uncertainty and supply chain recalibration. Regarding US tariffs, management stated the situation is complicated and they are monitoring it, but the underlying trend of outsourcing (China Plus One, Europe Plus One, US Plus One) continues to drive inquiries. Hikal has also responded to US FDA observations received in February, confirming no data integrity issues, and is awaiting the FDA's response.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.